Dual roles of TLR7 in the lung cancer microenvironment

OncoImmunology

Volumn 4, Issue 3, 2015, Pages 1-3

  Dajon, Marion ^a,b,c   Iribarren, Kristina ^a,b,c   Cremer, Isabelle ^a,b,c  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Chemoresistance; Lung cancer; MDSC; TLR7

Indexed keywords

CYCLIN B1; CYCLIN D1; IMIQUIMOD; LOXORIBINE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P16; PROTEIN P27; PROTEIN P53; TOLL LIKE RECEPTOR 7;

ARTICLE; CARCINOGENESIS; CELL ACTIVATION; CELL MATURATION; CELL PROLIFERATION; HUMAN; LUNG ADENOCARCINOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; ONCOGENE C MYC; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 84954525988     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/2162402X.2014.991615     Document Type: Article

References (10)

1. Wang D, Precopio M, Lan T, Yu D, Tang JX, Kandimalla ER, Agrawal S. Antitumor activity and immune response induction of a dual agonist of Toll-like receptors 7 and 8. Mol Cancer Ther 2010 Jun; 9(6):1788-97; PMID:20515950; http://dx.doi.org/10.1158/1535-7163.MCT-09-1198
2. Koga-Yamakawa E, Dovedi SJ, Murata M, Matsui H, Leishman AJ, Bell J, Ferguson D, Heaton SP, Oki T, Tomizawa H, et al. Intratracheal and oral administration of SM-276001: a selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer. Int J Cancer J Int Cancer 2013 Feb 1; 132 (3):580-90; PMID:22733292; http://dx.doi.org/10.1002/ijc.27691
3. Le Mercier I, Poujol D, Sanlaville A, Sisirak V, Gobert M, Durand I, Dubois B, Treilleux I, Marvel J, Vlach J, et al. Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment. Cancer Res 2013 Aug 1; 73(15):4629-40; PMID:23722543; http://dx.doi.org/10.1158/0008-5472.CAN-12-3058
4. Serra-Guillén C, Nagore E, Hueso L, Traves V, Messeguer F, Sanmartín O, Llombart B, Requena C, Botella-Estrada R, Guillén C. A randomized pilot comparative study of topical methyl aminolevulinate photodynamic therapy versus imiquimod 5% versus sequential application of both therapies in immunocompetent patients with actinic keratosis: clinical and histologic outcomes. J Am Acad Dermatol 2012 Apr; 66(4):131-7; PMID:22226430; http://dx.doi.org/10.1016/j.jaad.2011.11.933
5. Narayan R, Nguyen H, Bentow JJ, Moy L, Lee DK, Greger S, Haskell J, Vanchinathan V, Chang PL, Tsui S, et al. Immunomodulation by imiquimod in patients with high-risk primary melanoma. J Invest Dermatol 2012 Jan; 132(1):163-9; PMID:21850019; http://dx.doi.org/10.1038/jid.2011.247
6. Cherfils-Vicini J, Platonova S, Gillard M, Laurans L, Validire P, Caliandro R, Magdeleinat P, Mami-Chouaib F, Dieu-Nosjean MC, Fridman WH, et al. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clin Invest. 2010 Apr; 120(4):1285-97; PMID:20237413; http://dx.doi.org/10.1172/JCI36551
7. Chatterjee S, Crozet L, Damotte D, Iribarren K, Schramm C, Alifano M, Lupo A, Cherfils-Vicini J, Goc J, Katsahian S, et al. TLR7 promotes tumor progression, chemotherapy resistance, and poor clinical outcomes in non-small cell lung cancer. Cancer Res 2014 Sep 15; 74(18):5008-18; PMID:25074614; http://dx.doi.org/10.1158/0008-5472.CAN-13-2698
8. Ochi A, Graffeo CS, Zambirinis CP, Rehman A, Hackman M, Fallon N, Barilla RM, Henning JR, Jamal M, Rao R, et al. Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. J Clin Invest. 2012 Nov 1; 122(11):4118-29; PMID:23023703; http://dx.doi.org/10.1172/JCI63606
9. Mohamed FE, Al-Jehani RM, Minogue SS, Andreola F, Winstanley A, Olde Damink SWM, Habtesion A, Malagö M, Davies N, Luong TV, et al. Effect of tolllike receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma. Liver Int Off J Int Assoc Study Liver 2014 Jul 2; PMID:24990399; 10.1111/liv.12626
10. Kelly MG, Alvero AB, Chen R, Silasi D-A, Abrahams VM, Chan S, Visintin I, Rutherford T, Mor G. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 2006 Apr 1; 66(7):3859-68; PMID:16585214; http://dx.doi.org/10.1158/0008-5472.CAN-05-3948